production capacity of Phase 1 and 2 was expanded, which led to solid revenue growth and profitability. We experienced a number of challenging factors that occurred at the same time, such as production of new

solution and other medical product manufacturing and trading business. Previously the company held 44% of all shares. Later in February 2018, the company acquired additional shares from one of the

weaker from protectionist trade policies between US and China and effect of Baht appreciation, which affected to export sector and industrial sector, especially in electronic components manufacturing

ดี ในช่วงที่ผ่านมา บริษัทหลักทรัพย์บางแห่งยังเปิดเผยข้อมูลทั้ง 2 ประการข้างต้นไม่ชัดเจนเท่าที่ควร ในการนี้ สำนักงานจึงขอความร่วมมือจากบริษัทท่านให้ความสำคัญกับการเปิดเผยข้อมูลดังกล่าวให้มากขึ้น

increase of gross profit compared with 3 month and six month period of the previous year. Cost of Sales Cost of sales in Q2 sees the increase in production. Even though the Baht have strengthened

%.  Revenue from production cosmetic products was THB 21.74 Million having decrease by 12.11%.  Revenue from network marketing business was THB 79.49 Million having growth by 77.74% The revenue of each

increased emphasis on leadership development are the key strategic priorities for the group. 4Q19 IVL Performance Summary IVL reported 2.9 MT of production volume in 4Q19 (-8ppt. organic and +10ppt. inorganic

External Customers 101.67 105.04 -3.36 -3.20% Net Profit for the Period 7.31 10.20 -2.89 -28.31% 3. Manufacturing and Selling of Tooling and Metal Fabrication unit: THB million 2020 2019 Change (THB million

strategy both in term of product and customer; and 4) a new manufacturing line which will be ready for production in Q4/2017. The new manufacturing line is currently the world’s best technology and will

improve from spending in all categories, consistent with the expansion of manufacturing production in both domestic and export-related industries. Exports in the first three months have jumped 11.3% year on